trending Market Intelligence /marketintelligence/en/news-insights/trending/q5GGmkxtHFH9MQpzNS7LcQ2 content esgSubNav
In This List

Oxford Immunotec to repurchase $100M ordinary shares

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Oxford Immunotec to repurchase $100M ordinary shares

Oxford Immunotec Global PLC said its board approved the repurchase up to $100 million of the company's ordinary shares within a five-year period.

The share repurchase program, intended to enhance shareholder value, is subject to shareholder approval at the company's annual general meeting scheduled for June 18.

The transaction will be financed using some of the proceeds from the sale of Oxford Immunotec's U.S. laboratory services business in November 2018, CEO Peter Wrighton-Smith said.

U.K.-based Oxford Immunotec is a diagnostics company focused on developing and commercializing proprietary tests for underserved immune-regulated conditions.